Table 2.
Adverse events
| Adverse events | Total patients | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|---|---|
| Treatment-related (injection site) | 8 | 8 | 0 | 0 | 0 | 0 |
| Any serious adverse events* | 5 | 0 | 1 | 3 | 0 | 1 |
| DIC | 1 | 0 | 0 | 0 | 0 | 1 |
| Abdominal pain | 1 | 0 | 0 | 1 | 0 | 0 |
| Intestinal perforation | 1 | 0 | 0 | 0 | 0 | 1 |
| Endometritis | 1 | 0 | 1 | 0 | 0 | 0 |
| Pneumonia | 1 | 0 | 0 | 1 | 0 | 0 |
| Pathologic fracture | 1 | 0 | 0 | 1 | 0 | 0 |
Abbreviation: DIC = disseminated intravascular coagulation.
*
Before starting study treatment, 1 patient developed grade 3 febrile neutropenia and 1 patient developed grade 3 diarrhea. These patients were not included in the analysis.